With trio of COVID deals, Merck takes a page from its Ebola strategy

Merck’s strategy to tackle COVID-19 appears to echo an approach that allowed the pharma to rapidly develop a vaccine for Ebola -- but on a much faster timeline.

Merck & Co. Inc. (NYSE:MRK) said Tuesday it is expanding its toolbox to fight COVID-19 via a trio of deals that gives the pharma two vaccine candidates and an antiviral therapeutic that could rival Gilead’s remdesivir...